Building a better tomorrow for individuals struggling with alcohol dependence and substance use disorders
 Learn More Psilocybin: A Promising Treatment for Substance Use Disorders

Home

About
OUR MISSION
Making better treatment options a reality
B. More Inc., a 501 (c) (3) non-profit lifescience company, is relentlessly focused on the development and commercialization of psychedelic medicines that offer the potential to dramatically improve lives of tens of millions of people struggling with alcoholism (alcohol use disorder/AUD) and other substance abuse disorders.
00.0

Americans struggle with alcoholism each year

0.0

people worldwide seek treatment for alcoholism each year

00

of individuals with alcoholism relapse to heavy drinking within the first year of seeking treatment

000

deaths are attributed to AUD every year in the US alone

000

dollars lost in annual workplace productivity, healthcare, and other costs in the US alone

Alcohol use disorder affects an estimated 27.9 million Americans aged 12 and older, and excessive alcohol use is linked to roughly 178,000 deaths in the United States each year, at an estimated economic cost of $249 billion annually. Sources: National Institute on Alcohol Abuse and Alcoholism, Alcohol Facts and Statistics; Centers for Disease Control and Prevention, Alcohol-Related Disease Impact.

About
Work
OUR APPROACH

Transforming best-in-class research into cutting-edge medicine

In partnership with world-leading addiction researchers at the NYU School of Medicine, B. More is undertaking clinical research with synthetic psilocybin (SYNP-101) to establish its safety and efficacy in treating alcoholism, OCD and other substance use disorders.

Our Approach
WHO WE ARE

Innovators in psychedelic drug development

Founded by philanthropists who have pioneered psychedelic research at some of the world’s leading medical schools, B. More has built a team that is leveraging decades of expertise in every aspect of pharmaceutical development and commercialization. We are leading the charge to ensure that the game-changing promise of our clinical research program becomes a reality for those in need of better treatment options.

Who We Are
Work
Skip to content